Clarifi in the news
Non-invasive and easily administered saliva test
Accelerates the diagnostic process with results in 3 to 6 weeks
Differentiates between autism and other developmental delays
Measures epigenetic molecules in saliva
Peer-reviewed research and NIH funded
Is your child eligible for Clarifi?
Clarifi is currently available to children who meet the following eligibility requirements.
Suspicion of autism
Your child has had a positive screen for autism, such as MCHAT-R
Appropriate age range
Must be 18 months through 6 years of age
Meets geographic requirements
Clarifi is currently available in the U.S., excluding New York State
The road to Clarifi
Read about our team’s journey to find a science based, objective, diagnostic tool for autism spectrum disorder.
Rising autism prevalence and
longer wait times for diagnosis
According to the CDC, 1 in 59 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. Health care providers need more specific, objective tools to diagnose ASD at younger ages to expedite treatment services.
“There has clearly been an increase in prevalence of autism spectrum disorder in our society. Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes and quality of life.”
Randall Carpenter, MD
Executive Vice President Clinical Development at Quadrant Biosciences
Cutting-edge breakthroughs in epigenetic research
Clarifi is not a genetic test. It is the product of game-changing scientific advancements in the area of epigenetics; the factors that influence how genes are turned on and off. Our peer-reviewed, NIH funded research discovered that certain RNA molecules that regulate genetic activity and reflect interactions between a patient and their environment, were different in children with autism.
“In too many cases children may not receive a diagnosis until they are 5 years old. Early diagnosis is critical for children with autism, and primary care providers play an important role in that initial process.”
Kristin Sohl, MD, FAAP
Associate Professor, Clinical Child Health – Vice Chair for Quality Improvement, Child Health Department – Advocacy Director, Child Health Department – Director, ECHO Autism
Translating the science into practical solutions
The next step was turning this breakthrough technology into a publicly available test. To accomplish this, Admera Health, a CLIA-certified Laboratory, developed and validated the Clarifi test by incorporating Quadrant Biosciences’ unique bioinformatics platform.
First ever objective epigenetic
test for autism
Clarifi can be used in children with a clinical suspicion or positive screen for autism (e.g., M-CHAT-R), to help determine the urgency of a specialist referral. In children with more obvious autism symptoms, a positive Clarifi test may give health care providers the confidence necessary to diagnose a child with autism and start beneficial therapies earlier.
“A test which can separate children who have screened M-CHAT positive into high likelihood of autism or low likelihood of autism could help streamline waitlists and permit earlier diagnosis and enrollment in autism treatment.”
Dr. Daniel Coury MD
Professor of Pediatrics and Psychiatry at College of Medicine at The Ohio State University and the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital
Diagnosis is only the first step
Quadrant Biosciences is proud to support Autism Speaks in providing resources and solutions to individuals and families touched by autism. In your patient account, you will find links to resources such as toolkits, local service provider directories and other helpful information.
Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the lifespan, for the needs of individuals and their families.
We’ve partnered with top
research and support organizations
Quadrant Biosciences is privileged to be aligned with a number of top autism research and support organizations
“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”
Richard Uhlig Founder and CEO
Quadrant Biosciences Inc.
Clarifi is coming soon
Sign up to be notified as soon as the test is available.